Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 0.78 |
| ▸ | GNA15 | P30679 | 1/20 | 0.61 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.61 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.61 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.61 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204995 | 0.92 | FFAR1 (0.79) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL205796 | 0.89 | FFAR1 (0.78) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL204824 | 0.88 | FFAR1 (0.75) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL10265578 | 0.87 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL205755 | 0.87 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL2689449 | 0.86 | FFAR1 (0.87) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL14309262 | 0.86 | FFAR1 (0.87) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL204944 | 0.86 | FFAR1 (0.76) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL207180 | 0.84 | FFAR1 (0.76) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL203834 | 0.84 | FFAR1 (0.67) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431367-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120046338-A1 | FUSED CYCLIC COMPOUNDS | YASUMA TSUNEO (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2041123-B1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-8088821-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | FFAR1 15/4885GNA15 584/4885SLC10A1 86/4885 |
| US-20120046338-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | FFAR1 15/4885GNA15 584/4885SLC10A1 86/4885 |
| US-20100197761-A1 | Fused cyclic compounds | GPR119, GLP1R, GPR65 | FFAR1 15/4885GNA15 584/4885SLC10A1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.